The DOI matches its Crossref record; 147 of the 161 references it cites were found in a registry or an index; 45 of the 76 sources its claims cite were checked for support.
SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia
Open accessAbstract
Background: Specific phobias impact over 400 million people worldwide. Digitalizing mental health could alleviate the burden. Still, although the corporate-driven Metaverse is expanding rapidly, there needs to be more momentum in harnessing virtual reality exposure therapy uptake. Objective: This study aims to conceptualize, develop, and deploy a free Virtual Reality Exposure Therapy (VRET) application specifically designed for treating acrophobia and claustrophobia. This pilot study, which holds the promise of a future where mental health is more accessible and effective, explores the feasibility of leveraging transdisciplinary collaboration among specialists to create a safe, accessible, and effective VRET solution. Methods: We conducted a Delphi heuristic approach involving bioethicists, neuroscientists, and tech developers. Second, we reviewed the existing psychological theories and therapeutic strategies for addressing phobias in VR. Third, we conceptualized a thematic analysis-derived framework for a safe, adaptive-gamified free exposure to virtual reality acrophobia and claustrophobia (SAFEvR ACT). Finally, we provide an overview of the iterative improvements made during 12 workshops and 76 weekly briefings on developmental implementations. Results: We developed the SAFEvR ACT into a proof-of-concept application freely deployed on the MentalVerse app platform. Our safety-focused approach can benefit from prevalidation perspectives within future randomized control trials. Conclusions: The resulting application derived from the SAFEvR ACT framework represents a blueprint to counter the current lack of iVR mental health uptake by offering a free VRET alternative. Future research should aim towards developing similar free platforms to lessen mental health burdens and gather quantitative data. We conclude with a call to action to researchers to fine-tune our current approach and take a stand for free digital mental health within MentalVeRse.app. © 2024 by the authors.
Overview
CoChat Summary
## TL;DR
The paper describes the design and deployment of SAFEvR ACT, a free, immersive VR exposure therapy app for acrophobia and claustrophobia, built through transdisciplinary Delphi-style workshops. It presents the app as a proof-of-concept and argues that safety-focused, adaptive gamification can improve VRET accessibility and engagement.
## Key findings
- The team conducted a Delphi research-and-development process with 12 workshops involving 10 specialists between October 2022 and March 2024, plus 76 weekly in-person meetings or video briefings to implement feedback.
- The resulting application was deployed on MentalVerse.app, is reported as compatible with Windows and Android, and requires a dedicated HMD; the authors recommend Oculus Quest 2 as the minimum requirement.
- The paper reports that the framework was transitioned into a proof-of-concept application freely available on the platform, and that the current version emphasizes safety prioritization and adaptive gamification.
- The authors argue the app addresses a gap in VRET uptake because freely available apps for acrophobia or claustrophobia are described as either not scientifically validated / not developed for clinical use or biased toward smartphone delivery.
## Methods
- Design: Delphi heuristic development approach combined with transdisciplinary workshops, thematic analysis, and iterative implementation of stakeholder feedback.
- Sample/data: 10 specialists from bioethics, neuroscience, mental health, and tech development participated in 12 workshops; implementation work continued in 76 weekly meetings/briefings.
- Main analysis: Thematic analysis of workshop feedback was used to refine the SAFEvR ACT conceptual framework, app features, safety elements, gamification, and psychotherapeutic prompts before deployment.
## Limitations
- The paper states that initial testing relied on a narrow specialist user group of neuroscientists, mental health professionals, and tech developers, and that there was no need for extensive empirical validation at this stage.
- It also states the app focuses solely on acrophobia and claustrophobia and depends on advanced iVR technology that may not be accessible to all users.
- The text makes evident that this is a development/proof-of-concept study rather than an outcomes trial: no patient sample, symptom-change data, or efficacy statistics are reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
29 Valid · 7 Not valid · 14 Not checked · 30 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“VRET undoubtedly delivers an advantage to practitioners compared to traditional exposure, as it is sometimes almost impossible to fine-tune exposure levels in real-world scenarios [30].”
§ SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia > 1. Introduction > 1.2. State-of-the-Art Virtual Reality Exposure Therapy (VRET)
What the sources say
- Partly supportedcites [30] Dellazizzo, 2020, Evidence on Virtual Reality-Based Therapies for Psychiatric Disorders: Meta-Review of Meta-Analyses, J. Med. Internet Res. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says VR lets therapists better control exposure content, rhythm, and repetition than classical or in vivo exposure. The Introduction also describes a high level of control over exposure parameters. Neither passage says fine-tuning exposure in real-world scenarios is sometimes almost impossible. (LLM, conf=0.83)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“with evidence showing substantial improvements in therapeutic outcomes [23].”
§ SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia > 1. Introduction > 1.2. State-of-the-Art Virtual Reality Exposure Therapy (VRET)
What the sources say
- Supportedcites [23] Demir, 2023, Efficacy of Virtual Reality Exposure Therapy in the Treatment of Specific Phobias: A Systematic Review, Psikiyatr. Guncel Yaklasimlar—Curr. Approaches Psychiatry source
The Discussion reports that the reviewed studies found virtual reality exposure therapy effective in reducing specific-phobia symptoms. The Effectiveness of Interventions section reports significantly greater symptom reductions than waitlist or placebo controls in several phobias, supporting the claim of improved therapeutic outcomes with VR-based treatment. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Nevertheless, iVR technologies can be beneficial adjuncts, especially when traditional therapies are challenging to access [40].”
§ SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia > 1. Introduction > 1.2. State-of-the-Art Virtual Reality Exposure Therapy (VRET)
What the sources say
- Supportedcites [40] Premkumar, P., Anderson, L., Brown, D., and Sumich, A. (2022). Editorial: The Use of Virtual-Reality Interventions in Reducing Anxiety. Front. Virtual Real., 3. source
The Introduction (section 1; page unavailable) describes VR therapy as a viable intervention for anxiety and says it offers accessibility benefits for people less inclined to use face-to-face therapy or unlikely to qualify for clinical referral. The Efficacy section (section 3; page unavailable) also describes benefits from VR used during chemotherapy. Together, these support the qualified claim that VR can be beneficial alongside care when conventional therapy is difficult to access. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For example, the experience might induce visually induced motion sickness (VIMS) characterized by nausea, dizziness, and disorientation, mainly containing sensory conflicts between the visual and vestibular systems [94,106].”
§ SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia > 4. Discussions > 4.1. Neurologist VRISE Mitigation Heuristics VR exposure may cause sensory overload [106,107], especially in susceptible individuals such as critically ill patients, where it might exacerbate their already enhanced sensory processing sensitivity [108]. For example, the experience might induce visually induced motion sickness (VIMS) characterized by nausea, dizziness, and disorientation, mainly containing sensory conflicts between the visual and vestibular systems [94,106]. In addition, lag or delay between virtual and real movements might decrease the sense of presence, impacting the user’s immersion and reducing the therapeutic benefit of iVR [109]. Colocation issues, such as when the user’s limbs are not aligned with the virtual ones depicted by controllers, can reduce the immersive benefit of VR, which is especially concerning for clinical pain management [110]. VR, where a person can feel embodied as an avatar, might not work for people with high proprioceptive acuity or aged individuals with more difficulties experiencing virtual embodiment in the first place [109]. Noise, light sources, or objects from the real world may also disrupt the sense of presence, thus decreasing the immersive quality [109]. Simulator sickness, a common adverse effect of prolonged iVR exposure that is similar to VIMS, is clinically expressed as a syndrome encompassing nausea, dizziness, headache, fatigue, and other symptoms, which might be more severe in older people and the Parkinson’s disease population [111,112]. Future research aims to investigate the role of iVR in assessing the risk of falling in Parkinson’s disease patients [113] and balance in the general population [114]. These symptoms have been thought to be caused by sensory conflicts and the reweighting of sensory signals, impacting perceptual estimates and potentially amplifying the severity of immersive cybersickness, especially in vulnerable patient situations, such as after undergoing surgical interventions [115]. Thus, despite these enormous therapeutic promises, considering these factors is imperative to mitigate adverse scenarios. A high correlation between the level of immersion and an increase in anxiety signifies a crucial factor of a more realistic experience for the future development of therapies using virtual reality. Furthermore, current graphical processing units’ unwritten law implies that a higher graphic fidelity correlates to lower frames per second, especially in standalone HMDs that lack high-end dedicated graphical processing power; a refresh rate measured constantly beyond 80 frames per second was therefore required by A.-M.G. as a means to ensure the mitigation of VRISE. With a significantly high cost for the resolution and embedding of additional environmental elements, this particular aspect led to a prolonged debate between the developers who were eager to harness more immersive elements. According to our safety-focused framework, the verdict was given by C.S. based on the motivation that “a high level of graphical fidelity immersion acquired at the price of refresh rate may not be suitable for self-exposure to VRET to preserve non-maleficence and mitigate adverse events”. Although no cybersickness mitigation method can entirely avoid this side effect of iVR exposure, as shown in Table 7, which results from neurologists’ literature reviews, A.-M.G. proposed a solution that led to a compromise consensus, resulting in the possibility of choosing „high” graphical quality that was found to be reasonable regarding consistency in frames per second. Therefore, the platform benefits from two Ginger iVR utilities freely available within the Unity Toolkit to ensure that user hardware is adaptable to cybersickness mitigation. First, the DotEffect Prefab tool establishes a common baseline (the frame of dots can be seen in the video abstract) in a virtual environment that will undoubtedly reduce the possible manifestations of simulation sickness. This concept allows the individual to focus on a stationary symbol in the simulated surroundings. Secondly, adding the SingleNose option perpetually uses an artificial nose in the user’s peripheral vision as a constant visual reminder anchor. As proven by the current literature, this implementation is likely to reduce the severity of cybersickness owing to a natural visual disturbance related to the positioning of one’s nose [100]. Concerning seizure mitigation, A.-M.G.’s extensive literature review has revealed a lack of evidence-based pharmacovigilance reports to bridge VR exposure to seizures; the SAFEvR ACT app is limited by the design of a red-derived chromatic theme.
What the sources say
- Supportedcites [94] Conner, 2022, Virtual Reality Induced Symptoms and Effects: Concerns, Causes, Assessment & Mitigation, Virtual Worlds source
The Introduction says VR can induce motion-sickness symptoms and includes visually induced motion sickness among the terms used for them. Section 4.4 lists nausea, disorientation, and dizziness as symptoms assessed for VRISE; Section 3.1 describes sensory conflict involving visual and vestibular feedback as a major proposed contributor, rather than an established sole cause. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [106] Poultney, 2022, The Experiencing Sensory Overload Project (ESOP): Developing an Immersive Simulation Experience for Healthcare Professionals, Int. J. Healthc. Simul. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Noise, light sources, or objects from the real world may also disrupt the sense of presence, thus decreasing the immersive quality [109].”
§ SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia > 4. Discussions > 4.1. Neurologist VRISE Mitigation Heuristics VR exposure may cause sensory overload [106,107], especially in susceptible individuals such as critically ill patients, where it might exacerbate their already enhanced sensory processing sensitivity [108]. For example, the experience might induce visually induced motion sickness (VIMS) characterized by nausea, dizziness, and disorientation, mainly containing sensory conflicts between the visual and vestibular systems [94,106]. In addition, lag or delay between virtual and real movements might decrease the sense of presence, impacting the user’s immersion and reducing the therapeutic benefit of iVR [109]. Colocation issues, such as when the user’s limbs are not aligned with the virtual ones depicted by controllers, can reduce the immersive benefit of VR, which is especially concerning for clinical pain management [110]. VR, where a person can feel embodied as an avatar, might not work for people with high proprioceptive acuity or aged individuals with more difficulties experiencing virtual embodiment in the first place [109]. Noise, light sources, or objects from the real world may also disrupt the sense of presence, thus decreasing the immersive quality [109]. Simulator sickness, a common adverse effect of prolonged iVR exposure that is similar to VIMS, is clinically expressed as a syndrome encompassing nausea, dizziness, headache, fatigue, and other symptoms, which might be more severe in older people and the Parkinson’s disease population [111,112]. Future research aims to investigate the role of iVR in assessing the risk of falling in Parkinson’s disease patients [113] and balance in the general population [114]. These symptoms have been thought to be caused by sensory conflicts and the reweighting of sensory signals, impacting perceptual estimates and potentially amplifying the severity of immersive cybersickness, especially in vulnerable patient situations, such as after undergoing surgical interventions [115]. Thus, despite these enormous therapeutic promises, considering these factors is imperative to mitigate adverse scenarios. A high correlation between the level of immersion and an increase in anxiety signifies a crucial factor of a more realistic experience for the future development of therapies using virtual reality. Furthermore, current graphical processing units’ unwritten law implies that a higher graphic fidelity correlates to lower frames per second, especially in standalone HMDs that lack high-end dedicated graphical processing power; a refresh rate measured constantly beyond 80 frames per second was therefore required by A.-M.G. as a means to ensure the mitigation of VRISE. With a significantly high cost for the resolution and embedding of additional environmental elements, this particular aspect led to a prolonged debate between the developers who were eager to harness more immersive elements. According to our safety-focused framework, the verdict was given by C.S. based on the motivation that “a high level of graphical fidelity immersion acquired at the price of refresh rate may not be suitable for self-exposure to VRET to preserve non-maleficence and mitigate adverse events”. Although no cybersickness mitigation method can entirely avoid this side effect of iVR exposure, as shown in Table 7, which results from neurologists’ literature reviews, A.-M.G. proposed a solution that led to a compromise consensus, resulting in the possibility of choosing „high” graphical quality that was found to be reasonable regarding consistency in frames per second. Therefore, the platform benefits from two Ginger iVR utilities freely available within the Unity Toolkit to ensure that user hardware is adaptable to cybersickness mitigation. First, the DotEffect Prefab tool establishes a common baseline (the frame of dots can be seen in the video abstract) in a virtual environment that will undoubtedly reduce the possible manifestations of simulation sickness. This concept allows the individual to focus on a stationary symbol in the simulated surroundings. Secondly, adding the SingleNose option perpetually uses an artificial nose in the user’s peripheral vision as a constant visual reminder anchor. As proven by the current literature, this implementation is likely to reduce the severity of cybersickness owing to a natural visual disturbance related to the positioning of one’s nose [100]. Concerning seizure mitigation, A.-M.G.’s extensive literature review has revealed a lack of evidence-based pharmacovigilance reports to bridge VR exposure to seizures; the SAFEvR ACT app is limited by the design of a red-derived chromatic theme.
What the sources say
- Could not verifycites [109] Sassaman, 2023, Sensory Reweighting: A Common Mechanism for Subjective Visual Vertical and Cybersickness Susceptibility, Virtual Real. sourceExperimental — accuracy not yet measured
The Introduction discusses cybersickness and sensory reweighting, while Apparatus and Stimuli describes the VR setup; neither addresses real-world noise, light, or objects disrupting presence. Searches for presence, immersion, and external distractions found no passage supporting the claimed effect on immersive quality. (LLM, conf=0.74)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
18 more claims · 4 with their cited sources checked
Create a free account to see all 80 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 42
- It may state two separate claims as one. 29
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia > Abstract
“deployed on the MentalVerse app platform. Our safety-focused approach can benefit from prevalidation perspectives within future randomized control”
§ SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia > 6. Patents
“The SAFEvR ACT App is available for modular collaborative development on the Association of Psychotherapy and Clinical Psychology websites: www.apipc.ro and https://MentalVeRse.app.”
Citations
Cites
Holmes, E. A., O'Connor, R. C., Perry, V. H., Tracey, I., Wessely, S., Arseneault, L., Ballard, C., Christensen, H., Cohen Silver, R., Everall, I., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30168-1 · Cited by 5,715 · cited 2×
“Moral and legal accountability [65,71] Data sovereignty [74] Technological and ethical barriers [82] Evidence-based design [78,79] -diagnosis Self-treatment Expectationbias [82] User safety ProfessionaloversightAccessibility [77,79,83,84] AgencyTrustPresence User-centered approach [85]…”
BackgroundA discussion of cybersickness in virtual environments
LaViola, J. J. (2000) · ACM SIGCHI Bulletin · doi:10.1145/333329.333344 · Cited by 1,426 · cited 1×
“Employ antihistamines such as dimenhydrinate, anti-nausea medications like ondansetron, and anticholinergics including scopolamine [117,118].”
BackgroundTorous, J., Bucci, S., Bell, I. H., Kessing, L. V., Faurholt‐Jepsen, M., Whelan, P., Carvalho, A. F., Keshavan, M., Linardon, J., & Firth, J. (2021) · World Psychiatry · doi:10.1002/wps.20883 · Cited by 1,199 · cited 3×
“Aspects derived from ISO Ergonomics of human–system interaction, Part 820: Ergonomic guidance on interactions in immersive environments, including augmented reality and virtual reality [49].”
BackgroundAffective interactions using virtual reality: the link between presence and emotions
Riva, G., Mantovani, F., Capideville, C. S., Preziosa, A., Morganti, F., Villani, D., Gaggioli, A., Botella, C., & Alcañiz, M. (2007) · CyberPsychology & Behavior · doi:10.1089/cpb.2006.9993 · Cited by 1,111 · cited 2×
“…barriers [82] Evidence-based design [78,79] -diagnosis Self-treatment Expectationbias [82] User safety ProfessionaloversightAccessibility [77,79,83,84] AgencyTrustPresence User-centered approach [85] Transparency, usability, and trustworthiness through design [45,86] iVR safe-check framework…”
BackgroundParsons, T. D., & Rizzo, A. A. (2008) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2007.07.007 · Cited by 994 · cited 2×
“The heterogenicity of designs leads to inconsistent quantitative data gathering, making it impossible to achieve higher hierarchical evidence-based conclusions through systematic reviews and meta-analysis [135].”
BackgroundVirtual reality exposure therapy for anxiety disorders: A meta-analysis
Powers, M. B., & Emmelkamp, P. M. G. (2008) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2007.04.006 · Cited by 904 · cited 1×
“Apply cognitive–behavioral strategies and anxiety management techniques and establish personalized iVR exposure limits [120] Use benzodiazepines such as lorazepam for acute anxiety management and SSRIs for long-term treatment of anxiety disorders [121,122] Conduct careful patient selection for iVR…”
BackgroundThe use of virtual reality technology in the treatment of anxiety and other psychiatric disorders
Maples-Keller, J. L., Bunnell, B. E., Kim, S.-J., & Rothbaum, B. O. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000138 · Cited by 862 · cited 1×
“…[77] Personalization and adaptability [78,79] Mitigating the risk of traumatizing or re-traumatizing participants [76]s Personalization of the parameters of the therapy [80] User autonomy [49,50,81] Privacy compared to in vivo exposure Personalized plan specific for the client [79] Table 3.”
BackgroundSharples, S., Cobb, S., Moody, A., & Wilson, J. R. (2008) · Displays · doi:10.1016/j.displa.2007.09.005 · Cited by 695
Virtual reality exposure therapy in anxiety disorders: a quantitative meta-analysis
Opriş, D., Pintea, S., García-Palacios, A., Botella, C., Szamosközi, Ş., & David, D. (2012) · Depression and Anxiety · doi:10.1002/da.20910 · Cited by 636
Why Cognitive Behavioral Therapy Is the Current Gold Standard of Psychotherapy
David, D., Cristea, I., & Hofmann, S. G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00004 · Cited by 565 · cited 1×
“CBT remains the primary treatment for anxiety disorders, including those of the specific phobia subtype, given its robust evidence base [39].”
Background
Research works printed but not linked: 5
- David, 2013, Prescriptive Index: Development and Validation of the Mood Wheel and Manager-Rational and Irrational Beliefs Scale, Romanian J. Appl. Psychol., 15, 41
- Zieglmeier, V., and Pretschner, A. (2021). Trustworthy Transparency by Design. arXiv.
- Furman, 2013, An Overview of the Treatment of Vestibular Disorders, NeuroRehabilitation, 32, 437
- Pavlou, 2009, The Effect of Virtual Reality Cognitive Training for Attention Deficit in Vestibular Rehabilitation: A Pilot Study, Otol. Neurotol., 30, 31
- Alexinschi, 2021, Perspective on the Double Edges of Virtual Reality in Medicine—Both Addiction & Treatment, BRAIN Broad Res. Artif. Intell. Neurosci., 12, 364
Cited by
From screens to scenes: A survey of embodied AI in healthcare
Liu, Y., Cao, X., Chen, T., Jiang, Y., You, J., Wu, M., Wang, X., Feng, M., Jin, Y., & Chen, J. (2025) · Information Fusion · doi:10.1016/j.inffus.2025.103033 · Cited by 92
Anser, M. K., Nabi, A. A., Ahmad, I., Abro, M. M. Q., & Zaman, K. (2025) · Health care science · doi:10.1002/hcs2.70018 · Cited by 46
Wallace, R., Lacey, C. J., & Sargisson, R. J. (2025) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2025.102056 · Cited by 3
Revolutionizing Scientific Research: The Role of AI and the Metaverse in Modern Discovery
Asrifan, A., & Ingilan, S. S. (2025) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-0340-6.ch001 · Cited by 2
Metaverse-Based Exposure Therapy and Social Anxiety: Perspectives from Young Psychotherapists
Cavallaro, A., Romano, M., & Frolli, A. (2025) · Journal of Technology in Behavioral Science · doi:10.1007/s41347-025-00548-5
Metadata
- Authors
- Gaina, M.-A., Sbarcea, S.-V., Popa, B.-S., Stefanescu, B.-V., Gaina, A.-M., Szalontay, A.-S., Bolos, A., & Stefanescu, C.
- Affiliations
- Psychiatry, Department of Medicine III, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 16 Universitatii Street, 700115 Iasi, Romania
- Faculty of Computer Science, “Alexandru Ioan Cuza” University, 700483 Iasi, Romania
- Alexandru Ioan Cuza University (RO)
- Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa” Iași, 700115 Iasi, Romania
- PhD Department, University of Medicine and Pharmacy “Grigore T. Popa” Iași, 700115 Iasi, Romania
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2024-06-27
- Volume
- 14
- Issue
- 7
- Pages
- 651
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC11274658
- OpenAlex
- W4400083062
- Semantic Scholar
- 0b9d3651962917e5112fe31650ef975c9baca746
- Cited by
- 9
- References
- 161
- Citations by year
- 2026: 2 · 2025: 7
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Medicine
- Topics
- Physical Sciences › Computer Science › Human-Computer Interaction › Virtual Reality Applications and Impacts
- Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- virtual reality exposure therapy, acrophobia, claustrophobia, specific phobia, immersive virtual reality, gamification, transdisciplinary collaboration, Delphi consensus, treatment safety, access to mental health care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia. https://app.cochat.ai/papers/10.3390/brainsci14070651
- The paper
- Gaina, M.-A., Sbarcea, S.-V., Popa, B.-S., Stefanescu, B.-V., Gaina, A.-M., Szalontay, A.-S., Bolos, A., & Stefanescu, C. (2024). SAFEvR MentalVeRse.app: Development of a Free Immersive Virtual Reality Exposure Therapy for Acrophobia and Claustrophobia. Brain Sciences. https://doi.org/10.3390/brainsci14070651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.